KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 71 filers reported holding KALA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.66 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $4,000 | +300.0% | 20,000 | +314.2% | 0.00% | – |
| Q2 2022 | $1,000 | -93.8% | 4,829 | -58.6% | 0.00% | – |
| Q1 2022 | $16,000 | – | 11,657 | +1165600.0% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 1 | -100.0% | 0.00% | – |
| Q1 2021 | $3,875,000 | -17.4% | 574,900 | -17.0% | 0.00% | – |
| Q4 2020 | $4,694,000 | -82.0% | 692,400 | -80.1% | 0.00% | -100.0% |
| Q3 2020 | $26,043,000 | -47.0% | 3,472,370 | -25.8% | 0.00% | -40.0% |
| Q2 2020 | $49,169,000 | +96.2% | 4,678,383 | +64.1% | 0.01% | +66.7% |
| Q1 2020 | $25,065,000 | +700.0% | 2,851,516 | +798.4% | 0.00% | – |
| Q3 2018 | $3,133,000 | -50.3% | 317,400 | -30.9% | 0.00% | -100.0% |
| Q2 2018 | $6,305,000 | -13.3% | 459,200 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $7,269,000 | -34.5% | 459,200 | -23.5% | 0.00% | 0.0% |
| Q4 2017 | $11,094,000 | -19.0% | 600,000 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $13,704,000 | – | 600,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |